GAR1
H/ACA ribonucleoprotein complex subunit 1
Also known as: GAR1_HUMAN, NOLA1
Cross-references: UniProt · Ensembl · Human Protein Atlas · GeneCards · NCBI Gene
Protein identityUniProt · HPA
- UniProt accession
- Q9NY12
- Gene
- GAR1
- Ensembl
- ENSG00000109534
- Chromosome
- 4
- Canonical length
- 217 aa
- Protein class
- Plasma proteins, Predicted intracellular proteins
- Subcellular location
- Nucleoplasm,Nucleoli fibrillar center
OverviewNCBI Gene
This gene is a member of the H/ACA snoRNPs (small nucleolar ribonucleoproteins) gene family. snoRNPs are involved in various aspects of rRNA processing and modification and have been classified into two families: C/D and H/ACA. The H/ACA snoRNPs also include the DKC1, NOLA2 and NOLA3 proteins. These four H/ACA snoRNP proteins localize to the dense fibrillar components of nucleoli and to coiled (Cajal) bodies in the nucleus. Both 18S rRNA production and rRNA pseudouridylation are impaired if any one of the four proteins is depleted. These four H/ACA snoRNP proteins are also components of the telomerase complex. The encoded protein of this gene contains two glycine- and arginine-rich domains and is related to Saccharomyces cerevisiae Gar1p. Two splice variants have been found for this gene. [provided by RefSeq, Jul 2008]
Canonical amino-acid sequenceUniProt
217 residues, UniProt reviewed canonical sequence.
>Q9NY12|GAR1
1 MSFRGGGRGG FNRGGGGGGF NRGGSSNHFR GGGGGGGGGN FRGGGRGGFG RGGGRGGFNK
61 GQDQGPPERV VLLGEFLHPC EDDIVCKCTT DENKVPYFNA PVYLENKEQI GKVDEIFGQL
121 RDFYFSVKLS ENMKASSFKK LQKFYIDPYK LLPLQRFLPR PPGEKGPPRG GGRGGRGGGR
181 GGGGRGGGRG GGFRGGRGGG GGGFRGGRGG GFRGRGHLocalizationUniProt · AlphaFold · HPA
Whether an antibody against GAR1 can act on the native protein depends on physical access: surface and secreted proteins are reachable by circulating antibodies, intracellular proteins usually are not.
- Antibody reachability
- Intracellular
- Secreted
- No
- Transmembrane segments
- 0
- Mean surface accessibility (rSASA)
- 0.57
- Highest tissue expression
- 30 nTPM
Expression across tissuesHPA
Tissue
- bone marrow: 30 nTPM
- esophagus: 21 nTPM
- skin: 21 nTPM
- liver: 15 nTPM
- adrenal gland: 15 nTPM
- urinary bladder: 15 nTPM
Single-cell type
- syncytiotrophoblasts: 117 nCPM
- migrating cytotrophoblasts: 93 nCPM
- erythrocyte progenitors: 91 nCPM
- esophageal basal cells: 91 nCPM
- cytotrophoblasts: 85 nCPM
- esophageal suprabasal cells: 83 nCPM
Immune cell
- memory B-cell: 8.5 nTPM
- naive B-cell: 8 nTPM
- basophil: 7.6 nTPM
- NK-cell: 7.3 nTPM
- T-reg: 6.9 nTPM
- plasmacytoid DC: 6.8 nTPM
Brain region
- white matter: 4.8 nTPM
- cerebral cortex: 4.5 nTPM
- hypothalamus: 4.5 nTPM
- pons: 4.3 nTPM
- medulla oblongata: 4.1 nTPM
- choroid plexus: 4 nTPM
Genetic constraint and essentialitygnomAD · DepMap
Does the body need this protein intact? Low LOEUF or a strong DepMap dependency means loss or blockade of the protein is likely to be felt.
- gnomAD LOEUF (loss-of-function intolerance)
- 0.69
- gnomAD pLI
- 0.1
- gnomAD missense Z
- 0.23
- DepMap mean gene effect
- -0.61
- DepMap dependency class
- common
Cancer expressionTCGA
Across TCGA tumor cohorts, this protein is over-expressed in roughly 4% of surveyed tumor types (aggregate summary; per-cohort expression, alteration, and survival load in the interactive view).
OntologyGO
Biological processes
Molecular functions
Cellular components
Protein domainsUniProt · Pfam · InterPro
KeywordsUniProt
InteractionsUniProt · HPA
Protein binding partners of GAR1 in the human serome: UniProt-annotated complex subunits plus reported interactors. Each links to its own Seroatlas record.
Antibody and autoantibody relevanceSeroatlas analysis
Seroatlas reads GAR1 as an antibody target. Whether an autoantibody or antibody against GAR1 could matter depends on whether native GAR1 is physically reachable, whether the body needs it intact, and whether it acts in a disease-relevant tissue.
GAR1 is annotated as predominantly intracellular. Intracellular proteins are common autoantibody markers, becoming visible to the immune system after cell injury or altered processing, but are usually markers of disease rather than direct drivers.
Annotation status
The present source text does not explicitly label GAR1 as an autoantigen. Seroatlas presents hypothesis context only and does not manufacture a known-serology claim.
Loading the interactive Seroatlas protein explorer...